Wortham Laboratories Inc.

Contact: Leon Wortham - CEO
Address: 6340 Bonny Oaks Dr., Chattanooga, Tennessee 37416, USA
Phone: +1-(423)-296-0090 | Fax: +1-(423)-296-0188 | Map/Directions >>

Profile: Wortham Laboratories Inc. deals with research, development and manufacture of medical devices, clinical diagnostic, & pharmaceutical products. We provide hemostatic, bio-adhesive, coagulation and factor replacement therapy drugs.

8 Products/Services (Click for related suppliers)  
• Abnormal Plasma Control (FDA Code: GGC / 864.5425)
A multipurpose system for in vitro coagulation studies is a device consisting of one automated or semiautomated instrument and its associated reagents and controls. The system is used to perform a series of coagulation studies and coagulation factor assays.
• Activated Partial Thromboplastin (FDA Code: GFO / 864.7925)
A partial thromboplastin time test is a device used for primary screening for coagulation abnormalities, for evaluation of the effect of therapy on procoagulant disorders, and as an assay for coagulation factor deficiencies of the intrinsic coagulation pathway.
• Collagen-Based Non-Absorbable Hemostatic Agent (FDA Code: LMG / 878.4490)
An absorbable hemostatic agent or dressing is a device intended to produce hemostasis by accelerating the clotting process of blood. It is absorbable.
• Fibrinogen Control Plasma (FDA Code: GIL / 864.7340)
A fibrinogen determination system is a device that consists of the instruments, reagents, standards, and controls used to determine the fibrinogen levels in disseminated intravascular coagulation (nonlocalized clotting within the blood vessels) and primary fibrinolysis (the dissolution of fibrin in a blood clot).
• Fibrinogen Determination System Test (FDA Code: KQJ / 864.7340)
• Normal Control Plasma (FDA Code: GIZ / 864.5425)
• Plasma Coagulation Control (FDA Code: GGN / 864.5425)
• Prothrombin Time Test (FDA Code: GJS / 864.7750)
A prothrombin time test is a device used as a general screening procedure for the detection of possible clotting factor deficiencies in the extrinsic coagulation pathway, which involves the reaction between coagulation factors III and VII, and to monitor patients receiving coumarin therapy (the administration of one of the coumarin anticoagulants in the treatment of venous thrombosis or pulmonary embolism).

 Edit or Enhance this Company (156 potential buyers viewed listing,  32 forwarded to manufacturer's website)
Browse Category   |   Alphabetical Products   |   ALL 25,000 Suppliers
HomeBuyAdd FREE ListingAdvertise Medical CompanyMedical Portal